Whitehawk Therapeutics (WHWK) Interest Coverage Ratio (2010 - 2024)
Whitehawk Therapeutics (WHWK) reported Interest Coverage Ratio of 352.97 for Q3 2024, down 14.7% year-over-year from 413.79 in Q4 2023, and down 31.37% on a QoQ basis from 268.69 in Q2 2024.
Whitehawk Therapeutics (WHWK) has 12 years of Interest Coverage Ratio data on file, last reported at 352.97 in Q3 2024.
- Quarterly Interest Coverage Ratio fell 14.7% year-over-year to 352.97 in Q3 2024, while the trailing twelve-month figure through Jun 2025 was 2692.87 (down 780.36% YoY) and the FY2024 annual result came in at 438.04, down 40.67% from the prior year.
- Interest Coverage Ratio slipped to 352.97 in Q3 2024 per WHWK's latest filing, from 268.69 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 29.59 in Q4 2020 and bottomed at 556.12 in Q3 2021.
- The 5-year median for Interest Coverage Ratio is 279.74 (2021), against an average of 243.66.
- The widest annual swing landed in 2021, when Interest Coverage Ratio tumbled 4682.26%; it then soared 53.38% in 2022.
- Tracing WHWK's Interest Coverage Ratio over 5 years: stood at 29.59 in 2020, then plunged by 1045.33% to 279.74 in 2021, then increased by 2.97% to 271.44 in 2022, then declined by 14.49% to 310.77 in 2023, then slipped by 13.58% to 352.97 in 2024.
- Per Business Quant, the three latest WHWK Interest Coverage Ratio figures stand at 352.97 (Q3 2024), 268.69 (Q2 2024), and 336.41 (Q1 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.88 |
| 10 | Whitehawk Therapeutics | 312.26 Mn | 189.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -352.97 |
| Jun 30, 2024 | -268.69 |
| Mar 31, 2024 | -336.41 |
| Dec 31, 2023 | -310.77 |
| Sep 30, 2023 | -307.74 |
| Jun 30, 2023 | -336.98 |
| Mar 31, 2023 | -290.09 |
| Dec 31, 2022 | -271.44 |
| Sep 30, 2022 | -259.24 |
| Jun 30, 2022 | -316.55 |
| Mar 31, 2022 | -238.17 |
| Dec 31, 2021 | -279.74 |
| Sep 30, 2021 | -556.12 |
| Jun 30, 2021 | -17.07 |
| Mar 31, 2021 | -18.25 |
| Dec 31, 2020 | 29.59 |
| Sep 30, 2020 | -11.63 |
| Dec 31, 2016 | -1,285.65 |
| Sep 30, 2016 | -1,949.60 |
| Jun 30, 2016 | -1,721.37 |
| Mar 31, 2016 | -1,756.66 |
| Dec 31, 2015 | -4.33 |
| Sep 30, 2015 | -1.97 |
| Jun 30, 2015 | -2.35 |
| Mar 31, 2015 | -2.14 |
| Dec 31, 2014 | -5.16 |
| Sep 30, 2014 | -2.87 |
| Jun 30, 2014 | -3.23 |
| Mar 31, 2014 | -2.54 |
| Dec 31, 2013 | -4.86 |
| Sep 30, 2013 | -2.69 |
| Jun 30, 2013 | -4.22 |
| Mar 31, 2013 | -3.82 |
| Dec 31, 2012 | -6.51 |
| Sep 30, 2012 | -3.70 |
| Jun 30, 2012 | -3.96 |
| Mar 31, 2012 | -3.74 |
| Dec 31, 2011 | -8.84 |
| Sep 30, 2011 | -5.99 |
| Jun 30, 2011 | -6.53 |
| Mar 31, 2011 | -4.80 |
| Dec 31, 2010 | -13.56 |
| Sep 30, 2010 | -8.01 |